{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:42:25Z","timestamp":1781592145246,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.semcancer.2021.02.009","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T11:14:02Z","timestamp":1613560442000},"page":"194-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0306-4328","authenticated-orcid":false,"given":"Marco","family":"Petrillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5847-8822","authenticated-orcid":false,"given":"Giulio","family":"Sozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Dessole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5523-8943","authenticated-orcid":false,"given":"Giampiero","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Dessole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Madonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Cherchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Chiantera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2021.02.009_bib0005","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0010","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0015","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0020","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1200\/JCO.1991.9.10.1801","article-title":"Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11912-012-0260-x","article-title":"Surgery for relapsed ovarian cancer: when should it be offered?","volume":"14","author":"Harter","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0030","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection","volume":"19","author":"Tian","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0035","series-title":"Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer version 1","year":"2020"},{"key":"10.1016\/j.semcancer.2021.02.009_bib0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2014.09.017","article-title":"Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial","volume":"136","author":"Lee","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0045","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2407-14-22","article-title":"Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomized controlled study","volume":"14","author":"van de Laar","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2021.02.009_bib0055","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann. Surg. Oncol."},{"issue":"May","key":"10.1016\/j.semcancer.2021.02.009_bib0060","article-title":"Molecular guided treatments in gynecologic oncology: analysis of a real-world precision cancer medicine platform","author":"Taghizadeh","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.semcancer.2021.02.009_bib0065","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ejca.2006.03.025","article-title":"Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations","volume":"42","author":"Ferrandina","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.semcancer.2021.02.009_bib0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2013.06.020","article-title":"Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors","volume":"131","author":"Petrillo","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0075","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ygyno.2014.05.029","article-title":"Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis","volume":"134","author":"Petrillo","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0080","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1245\/s10434-015-4523-2","article-title":"Secondary cytoreduction in platinum-resistant recurrent ovarian Cancer: a single-institution experience","volume":"22","author":"Musella","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0085","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.3390\/cancers12082239","article-title":"Cytoreductive surgery for heavily pre-treated, platinum-resistant epithelial ovarian carcinoma: a two-center retrospective experience","volume":"12","author":"Tuninetti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semcancer.2021.02.009_bib0090","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00268-007-9146-8","article-title":"Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients","volume":"31","author":"Cotte","year":"2007","journal-title":"World J. Surg."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0095","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1471-0528.2011.03207.x","article-title":"Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study","volume":"119","author":"Deraco","year":"2012","journal-title":"BJOG."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0100","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1245\/s10434-012-2510-4","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for persistent and recurrent advanced ovarian arcinoma: a multicenter, prospective study of 246 patients","volume":"19","author":"Bakrin","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0105","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","article-title":"Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients","volume":"39","author":"Bakrin","year":"2013","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ygyno.2019.06.014","article-title":"Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: an analysis of five prospective phase II\/III trials of NOGGO metadata base","volume":"154","author":"Canaz","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0115","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/SLA.0000000000002164","article-title":"Survival, healthcare utilization, and end-of-life care among older adults with malignancy-associated bowel obstruction: comparative study of surgery, venting gastrostomy, or medical management","volume":"267","author":"Lilley","year":"2018","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0120","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1089\/jpm.2014.0355","article-title":"Venting gastrostomy at home for symptomatic management of bowel obstruction in Advanced\/Recurrent ovarian malignancy: a case series","volume":"18","author":"DeEulis","year":"2015","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0125","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ygyno.2013.02.002","article-title":"Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement","volume":"129","author":"Diver","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0130","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2021.02.009_bib0135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2021.02.009_bib0140","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2016.03.037","article-title":"Targeting the hallmarks of ovarian cancer: the big picture","volume":"142","author":"Petrillo","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0145","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0150","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0155","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/ijgc-2018-000018","article-title":"Low grade serous ovarian carcinoma: identifying variations in practice patterns","volume":"29","author":"Siemon","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.semcancer.2021.02.009_bib0160","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0002-9378(97)70352-1","article-title":"Flow cytometric analysis of lymph node 329 metastases in advanced ovarian cancer: clinical and biologic significance","volume":"176","author":"Kimball","year":"1997","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0165","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mvr.2007.05.003","article-title":"Tumor microvasculature and microenvironment: targets for 332 anti-angiogenesis and normalization","volume":"74","author":"Fukumura","year":"2007","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0170","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0169-409X(00)00131-9","article-title":"Delivery of molecular and cellular medicine to solid tumors","volume":"46","author":"Jain","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0175","first-page":"3944","article-title":"Selective lethal effect of supranormal temperatures on human neoplastic cells","volume":"36","author":"Giovanella","year":"1976","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0180","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/02656739709023545","article-title":"Reduction of cellular cisplatin resistance by hyperthermia\u2014a review","volume":"13","author":"Hettinga","year":"1997","journal-title":"Int. J. Hyperth."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0185","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ejso.2006.03.011","article-title":"Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced\/recurrent ovarian cancer patients: the experience of National Cancer institute of Milan","volume":"32","author":"Raspagliesi","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0190","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0195","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/IGC.0000000000000864","article-title":"Brief report about the role of Hyperthermic Intraperitoneal Chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al","volume":"27","author":"Harter","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.semcancer.2021.02.009_bib0200","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/IGC.0b013e3181c50cde","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry","volume":"20","author":"Helm","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.semcancer.2021.02.009_bib0205","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ygyno.2013.12.028","article-title":"Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series","volume":"132","author":"Fagotti","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0210","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jmig.2014.11.008","article-title":"Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes","volume":"22","author":"Fagotti","year":"2015","journal-title":"J. Minim. Invasive Gynecol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0215","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"18","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0220","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(12)70567-3","article-title":"Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase III randomised trial","volume":"14","author":"Stark","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0225","first-page":"323","article-title":"Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer","volume":"2","author":"Jatoi","year":"2004","journal-title":"J. Support. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0230","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/ijgc-00009577-200509000-00019","article-title":"Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis","volume":"15","author":"Mangili","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.semcancer.2021.02.009_bib0235","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","article-title":"Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure","volume":"89","author":"Dedrick","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0240","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0090-8258(03)00073-8","article-title":"Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series","volume":"89","author":"Pothuri","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0245","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2007.11.035","article-title":"Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series","volume":"108","author":"Caceres","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0250","article-title":"Palliative surgery versus medical management for bowel obstruction in ovarian cancer","volume":"7","author":"Kucukmetin","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ygyno.2011.11.007","article-title":"Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC)","volume":"125","author":"Kolomainenen","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0260","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ygyno.2013.11.022","article-title":"Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience","volume":"132","author":"Tempfer","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0265","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.sla.0000218089.61635.5f","article-title":"High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis","volume":"244","author":"Esquis","year":"2006","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2021.02.009_bib0270","first-page":"6723","article-title":"Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin in women with peritoneal carcinomatosis: a cohort study","volume":"35","author":"Tempfer","year":"2015","journal-title":"Anticancer Res."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2021.02.009_bib0275","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6000","article-title":"Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III\/ENGOT-ov20","volume":"38","author":"Du Bois","year":"2020","journal-title":"Journal Clin Oncol"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X21000328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X21000328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:52:47Z","timestamp":1760917967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X21000328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":55,"alternative-id":["S1044579X21000328"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2021.02.009","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2021.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}